403 related articles for article (PubMed ID: 32909249)
1. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
2. Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis.
Gomes T; McCormack D; Kitchen SA; Paterson JM; Mamdani MM; Proulx L; Bayliss L; Tadrous M
CMAJ Open; 2021; 9(4):E1055-E1062. PubMed ID: 34815261
[TBL] [Abstract][Full Text] [Related]
3. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
[TBL] [Abstract][Full Text] [Related]
4. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
5. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
Chen HH; Yemeke T; Ozawa S
PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in Inflammatory Bowel Disease.
Buchner AM; Schneider Y; Lichtenstein GR
Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013
[TBL] [Abstract][Full Text] [Related]
7. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.
Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK
J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.
Gholami A; Azizpoor J; Aflaki E; Rezaee M; Keshavarz K
Biomed Res Int; 2021; 2021():4450162. PubMed ID: 34877355
[TBL] [Abstract][Full Text] [Related]
9. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Mansell K; Bhimji H; Eurich D; Mansell H
BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
[TBL] [Abstract][Full Text] [Related]
10. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
[No Abstract] [Full Text] [Related]
11. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
12. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL;
Lancet Rheumatol; 2024 Jul; 6(7):e438-e446. PubMed ID: 38843858
[TBL] [Abstract][Full Text] [Related]
14. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
[TBL] [Abstract][Full Text] [Related]
15. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
Kim SC; Sarpatwari A; Landon JE; Desai RJ
Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866
[No Abstract] [Full Text] [Related]
16. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
Berreur B; Guerin F; Christophe B; Limido G; Paubel P
Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
18. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
[TBL] [Abstract][Full Text] [Related]
19. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.
Stajszczyk M; Obarska I; Jeka S; Batko B
Ann Rheum Dis; 2023 Sep; 82(9):1171-1180. PubMed ID: 37328194
[TBL] [Abstract][Full Text] [Related]
20. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]